-
Mashup Score: 1
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than adults receiving semaglutide 2.4 mg, according to top-line results from the STEP UP phase 3b trial. The trial enrolled 1,407 adults with a BMI of 30 kg/m2 or higher and without diabetes. Participants were randomly assigned to once-weekly semaglutide 7.2 mg, once-weekly
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than adults receiving semaglutide 2.4 mg, according to top-line results from the STEP UP phase 3b trial. The trial enrolled 1,407 adults with a BMI of 30 kg/m2 or higher and without diabetes. Participants were randomly assigned to once-weekly semaglutide 7.2 mg, once-weekly
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🚨 Top-line results from the STEP UP trial showed a higher dose of #semaglutide for adults with #obesity conferred a 20.7% weight loss at 72 weeks vs. a 17.5% weight loss for adults taking a 2.4 mg dose. @novonordiskus @GoHealio https://t.co/XNnvM13nMu
-
🚨 Top-line results from the STEP UP trial showed a higher dose of #semaglutide for adults with #obesity conferred a 20.7% weight loss at 72 weeks vs. a 17.5% weight loss for adults taking a 2.4 mg dose. @novonordiskus @GoHealio https://t.co/XNnvM13nMu